PL3323427T3 - Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv) - Google Patents

Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv)

Info

Publication number
PL3323427T3
PL3323427T3 PL17194834T PL17194834T PL3323427T3 PL 3323427 T3 PL3323427 T3 PL 3323427T3 PL 17194834 T PL17194834 T PL 17194834T PL 17194834 T PL17194834 T PL 17194834T PL 3323427 T3 PL3323427 T3 PL 3323427T3
Authority
PL
Poland
Prior art keywords
hiv
immunodeficiency virus
human immunodeficiency
neutralizing antibodies
neutralizing
Prior art date
Application number
PL17194834T
Other languages
English (en)
Inventor
Po-Ying Chan-Hui
Jennifer Mitcham
Ole Olsen
Steven Frey
Matthew Moyle
Sanjay K. Phogat
Dennis Burton
Laura Marjorie Walker
Melissa D. de Jean de St. Marcel Simek-Lemos
Wayne Koff
Stephen KAMINSKY
Original Assignee
Theraclone Sciences, Inc.
The Scripps Research Institute
International Aids Vaccine Initiative
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theraclone Sciences, Inc., The Scripps Research Institute, International Aids Vaccine Initiative filed Critical Theraclone Sciences, Inc.
Publication of PL3323427T3 publication Critical patent/PL3323427T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • AIDS & HIV (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17194834T 2009-03-17 2010-03-17 Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv) PL3323427T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16101009P 2009-03-17 2009-03-17
US16582909P 2009-04-01 2009-04-01
US22473909P 2009-07-10 2009-07-10
US28566409P 2009-12-11 2009-12-11
EP10722810.8A EP2408476B1 (en) 2009-03-17 2010-03-17 Human immunodeficiency virus (hiv) -neutralizing antibodies
PCT/US2010/027695 WO2010107939A2 (en) 2009-03-17 2010-03-17 Human immunodeficiency virus (hiv) -neutralizing antibodies
EP17194834.2A EP3323427B1 (en) 2009-03-17 2010-03-17 Human immunodeficiency virus (hiv)-neutralizing antibodies

Publications (1)

Publication Number Publication Date
PL3323427T3 true PL3323427T3 (pl) 2021-10-11

Family

ID=42668183

Family Applications (4)

Application Number Title Priority Date Filing Date
PL17194834T PL3323427T3 (pl) 2009-03-17 2010-03-17 Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv)
PL10722810T PL2408476T3 (pl) 2009-03-17 2010-03-17 Przeciwciała neutralizujące ludzkiego wirusa niedoboru odporności (HIV)
PL17173548T PL3260136T3 (pl) 2009-03-17 2010-03-17 Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv)
PL18207707.3T PL3542817T3 (pl) 2009-03-17 2010-03-17 Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv)

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL10722810T PL2408476T3 (pl) 2009-03-17 2010-03-17 Przeciwciała neutralizujące ludzkiego wirusa niedoboru odporności (HIV)
PL17173548T PL3260136T3 (pl) 2009-03-17 2010-03-17 Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv)
PL18207707.3T PL3542817T3 (pl) 2009-03-17 2010-03-17 Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv)

Country Status (16)

Country Link
US (8) US9051362B2 (pl)
EP (5) EP3542817B1 (pl)
AU (5) AU2010226668B2 (pl)
CA (2) CA2980883C (pl)
CY (1) CY1121323T1 (pl)
DK (1) DK2408476T3 (pl)
ES (4) ES2848555T3 (pl)
HR (1) HRP20180027T1 (pl)
HU (1) HUE036031T2 (pl)
LT (1) LT2408476T (pl)
NO (1) NO2408476T3 (pl)
PL (4) PL3323427T3 (pl)
PT (4) PT3542817T (pl)
SI (4) SI3260136T1 (pl)
SM (1) SMT201800016T1 (pl)
WO (1) WO2010107939A2 (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
US20110212106A1 (en) * 2010-01-20 2011-09-01 Institute For Research In Bioscience Hiv-1 neutralizing antibodies and uses thereof
US8586056B2 (en) * 2010-03-02 2013-11-19 International Aids Vaccine Initiative HIV-1 envelope glycoprotein
CA3201524C (en) 2010-08-31 2026-01-13 International Aids Vaccine Initiative Human immunodeficiency virus (hiv)-neutralizing antibodies
WO2012040562A2 (en) 2010-09-24 2012-03-29 International Aids Vaccine Initiative Novel hiv-1 broadly neutralizing antibodies
EP2492279A1 (en) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
US10040826B2 (en) 2011-07-05 2018-08-07 Duke University Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens
US8791108B2 (en) * 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US20140348865A1 (en) 2011-09-12 2014-11-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Ser. Immunogens based on an hiv-1 v1v2 site-of-vulnerability
EP2763699A4 (en) * 2011-10-03 2015-05-20 Univ Duke VACCINE
EP2788026A4 (en) 2011-12-05 2015-08-05 Univ Duke V1V2 IMMUNOGENIC
CN104271597B (zh) 2011-12-08 2018-05-25 美国政府(由卫生和人类服务部的部长所代表) Hiv-1的中和抗体及其用途
US20150044137A1 (en) * 2012-03-23 2015-02-12 The United States of America, as represented by the Secretary, Dep. of Health Care Human Services Neutralizing antibodies to hiv-1 and their use
EP2698377A1 (en) 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Enhanced rapid immunogen selection method for HIV gp120 variants
WO2014134547A1 (en) * 2013-02-28 2014-09-04 Therabiol, Inc. Hiv antigens and antibodies
EP3010549A4 (en) * 2013-06-17 2017-03-15 Emory University Pathogen binding agents conjugated to radioisotopes and uses in imaging and therapeutic applications
WO2015048517A1 (en) * 2013-09-28 2015-04-02 Duke University Escape mutants
WO2015127108A1 (en) * 2014-02-19 2015-08-27 Duke University Trimeric hiv-1 envelopes compositions and uses thereof
US10093720B2 (en) 2014-06-11 2018-10-09 International Aids Vaccine Initiative Broadly neutralizing antibody and uses thereof
SI3166607T1 (sl) 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
CN110305133A (zh) 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
WO2016054023A1 (en) * 2014-09-29 2016-04-07 Duke University Hiv-1 antibodies and uses thereof (adcc and bispecific abs)
US20180263985A1 (en) 2015-09-15 2018-09-20 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
ES2768957T3 (es) 2015-09-24 2020-06-24 Abvitro Llc Composiciones de anticuerpos contra el VIH y métodos de uso
JP6732915B2 (ja) 2015-12-15 2020-07-29 ギリアード サイエンシーズ, インコーポレイテッド ヒト免疫不全ウイルス中和抗体
CN107022027B (zh) * 2016-02-02 2022-03-08 中国疾病预防控制中心性病艾滋病预防控制中心 Hiv-1广谱中和抗体及其用途
CN107033241B (zh) * 2016-02-03 2022-03-08 中国疾病预防控制中心性病艾滋病预防控制中心 Hiv-1广谱中和抗体及其用途
JP7009517B2 (ja) 2017-06-21 2022-01-25 ギリアード サイエンシーズ, インコーポレイテッド Hiv gp120およびcd3を標的とする多重特異性抗体
WO2018237357A1 (en) * 2017-06-22 2018-12-27 University Of Maryland, Baltimore HIV-LARGE SPECTRUM HIV NEUTRALIZATION ANTIBODIES AGAINST HIV
IL317993B2 (en) 2018-07-03 2025-11-01 Gilead Sciences Inc Antibodies directed against HIV gp120 and methods of use
US12365722B2 (en) 2018-10-19 2025-07-22 University Of Maryland, College Park Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope
CA3120324A1 (en) * 2018-12-04 2020-06-11 The Rockefeller University Hiv vaccine immunogens
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
US20230134571A1 (en) * 2019-10-29 2023-05-04 International Aids Vaccine Initiative Engineered antibodies to hiv env
US20210277093A1 (en) * 2020-03-09 2021-09-09 Adma Biologics, Inc. Immunotherapeutic compositions and methods of production for coronavirus
JP7518286B2 (ja) 2020-08-25 2024-07-17 ギリアード サイエンシーズ, インコーポレイテッド Hivを標的とする多重特異性抗原結合分子及び使用方法
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022162009A1 (en) 2021-01-26 2022-08-04 Eth Zurich Method for rapid identification of cross-reactive and/or rare antibodies
WO2022161597A1 (en) * 2021-01-26 2022-08-04 Eth Zurich Method for rapid identification of cross-reactive and/or rare antibodies
US20240181051A1 (en) * 2021-04-19 2024-06-06 The Wistar Institute Of Anatomy And Biology Sialydase linked hiv antibodies and methods of use
CA3259040A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. HIV Immunogenic Polypeptides and Vaccines and Their Uses
WO2026039311A1 (en) 2024-08-10 2026-02-19 Vectorgen Lentiviral vector for treating human immunodeficiency virus infection

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
AU8295491A (en) 1990-06-29 1992-01-23 Biosource Technologies Incorporated Melanin production by transformed microorganisms
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
AU4289496A (en) 1994-12-02 1996-06-19 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
US6824780B1 (en) 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
AU2004204462B2 (en) 2003-01-09 2012-03-08 Macrogenics, Inc. Dual expression vector system for antibody expression in bacterial and mammalian cells
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
US20070292390A1 (en) * 2004-10-29 2007-12-20 Dimitrov Dimiter S Broadly Cross-Reactive Hiv-1 Neutralizing Human Monoclonal Antibodies
CA3201524C (en) * 2010-08-31 2026-01-13 International Aids Vaccine Initiative Human immunodeficiency virus (hiv)-neutralizing antibodies

Also Published As

Publication number Publication date
AU2015234345A1 (en) 2015-11-05
DK2408476T3 (en) 2018-01-22
US20210040186A1 (en) 2021-02-11
AU2015234345B2 (en) 2017-09-21
PT3542817T (pt) 2022-07-05
US12312396B2 (en) 2025-05-27
EP2408476B1 (en) 2017-10-18
EP4085925A1 (en) 2022-11-09
EP3542817B1 (en) 2022-05-11
US10865234B2 (en) 2020-12-15
US20230295278A1 (en) 2023-09-21
CY1121323T1 (el) 2020-05-29
HRP20180027T1 (hr) 2018-04-20
US20190338017A1 (en) 2019-11-07
US12018067B2 (en) 2024-06-25
SI3260136T1 (sl) 2021-05-31
US10407493B2 (en) 2019-09-10
PL3542817T3 (pl) 2022-09-19
ES2656234T3 (es) 2018-02-26
US20110044994A1 (en) 2011-02-24
CA2980883A1 (en) 2010-09-23
EP2408476A2 (en) 2012-01-25
US10239934B2 (en) 2019-03-26
US9051362B2 (en) 2015-06-09
PT3260136T (pt) 2021-02-12
ES2916404T3 (es) 2022-06-30
AU2023204017B2 (en) 2026-04-09
US20240343782A1 (en) 2024-10-17
WO2010107939A2 (en) 2010-09-23
PT2408476T (pt) 2018-01-19
PL3260136T3 (pl) 2021-10-18
ES2848555T3 (es) 2021-08-10
US20190169273A1 (en) 2019-06-06
CA2755821A1 (en) 2010-09-23
EP3260136B1 (en) 2020-11-25
EP3260136A1 (en) 2017-12-27
US20150218257A1 (en) 2015-08-06
US20190031742A1 (en) 2019-01-31
CA2980883C (en) 2020-12-29
ES2848203T3 (es) 2021-08-05
SI3542817T1 (sl) 2022-09-30
SI2408476T1 (en) 2018-04-30
HUE036031T2 (hu) 2018-06-28
AU2010226668A1 (en) 2011-10-06
AU2015234345C1 (en) 2017-12-21
US9920111B2 (en) 2018-03-20
SMT201800016T1 (it) 2018-03-08
PT3323427T (pt) 2021-03-03
EP3323427B1 (en) 2021-01-13
WO2010107939A3 (en) 2011-05-26
NO2408476T3 (pl) 2018-03-17
AU2020210242B2 (en) 2023-04-06
EP3323427A1 (en) 2018-05-23
CA2755821C (en) 2017-11-14
AU2017264985B2 (en) 2020-05-07
AU2020210242A1 (en) 2020-08-20
EP3542817A1 (en) 2019-09-25
US11584789B2 (en) 2023-02-21
AU2017264985A1 (en) 2017-12-07
PL2408476T3 (pl) 2018-05-30
SI3323427T1 (sl) 2021-07-30
LT2408476T (lt) 2018-03-26
AU2010226668B2 (en) 2015-07-16
AU2023204017A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
LT2408476T (lt) Žmogaus imunodeficito virusą (živ) neutralizuojantys antikūnai
PT3556396T (pt) Anticorpos neutralizantes do vírus da imunodeficiência humana (vih)
AU2016202543A1 (en) Human immunodeficiency virus (hiv)-neutralizing antibodies
AP2011005944A0 (en) Inhibitors of human immunodeficiency virus replication.
PT3494972T (pt) Combinações de dolutegravir e lamivudina para o tratamento de infeção pelo hiv
DK3329772T3 (da) Dobbeltvektor til inhibering af human immundefektvirus
ZA201202116B (en) Neutralizing antibodies to hiv-1 and their use
IL217008A0 (en) Vaccine
SG10201508700XA (en) Recombinant subunit dengue virus vaccine
IL222228A0 (en) Hiv vaccine
ZA201002445B (en) Hiv preventive vaccine based on hiv specific antibodies
IL212311A0 (en) Immunoenhancer-linked oligomeric hiv vaccines
AP2013007180A0 (en) Truncated HIV envelope proteins (ENV), methods andcompositions related thereto
EP2635300A4 (en) DOCK-AND-LOCK (DNL) CONSTRUCTS FOR THERAPY AGAINST HUMAN IMMUNE WEAKAGE VIRUS (HIV)
IL216102A (en) Combined measles vaccine - malaria
ZA201105357B (en) Splitting gp41
GB0912950D0 (en) Virus
PT2643460T (pt) Métodos, composições e kits para determinação do virus da imunodeficiência humana (vih)
GB0901056D0 (en) Virus
AP3595A (en) Novel gp41 antigens
GB0911339D0 (en) Viral file transfer
GB0823560D0 (en) Virus
HK1178550A (en) Human group p immunodeficiency virus and uses thereof
GB201005057D0 (en) HIV-1 ENV-deactivating alpha-bodies
GB0920319D0 (en) HPV vaccine